[Form 4] Arcutis Biotherapeutics, Inc. Insider Trading Activity
Filing Impact
Filing Sentiment
Form Type
4
Insider Trade Summary
Net Seller: 28,750 shares ($432,700)
Net Sell
6 txns
Insider
Burnett Patrick
Role
See Remarks
Sold
28,750 shs ($433K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (right to buy) | 5,750 | $0.00 | -- |
| Exercise | Common Stock | 5,750 | $0.00 | -- |
| Sale | Common Stock | 5,750 | $15.0702 | $87K |
| Exercise | Stock Option (right to buy) | 23,000 | $0.00 | -- |
| Exercise | Common Stock | 23,000 | $0.00 | -- |
| Sale | Common Stock | 23,000 | $15.0455 | $346K |
Holdings After Transaction:
Stock Option (right to buy) — 172,500 shares (Direct);
Common Stock — 121,218 shares (Direct)
Footnotes (1)
- The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on December 12, 2024, by the Reporting Person, with a plan end date of February 27, 2026. The transaction was executed in multiple trades in prices ranging from $15.00 to $15.125, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. The transaction was executed in multiple trades in prices ranging from $15.00 to $15.17, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. On January 12, 2024, the Reporting Person was granted options, in which 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 12, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer.
